Clinical trial · Observational
Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer
Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer-Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The 18F-FDG-PET scan is currently being used for cancer diagnosis, staging, identifying hidden metastasis, and assessment of treatment responses in clinical oncology. Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In this study, the investigators prospectively determined clinical 18F-FDG-PET type according to degree of FDG-uptake in pancreatic cancer and compare oncologic outcomes between the types.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET-CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- K-type
- description
- FDG uptake in pancreatic cancer is similar to that of kidney
- interventionNames
- Device: PET-CT
- label
- non K-type
- description
- FDG uptake in pancreatic cancer is lower than that of kidney
- interventionNames
- Device: PET-CT
Primary outcomes (1)
- measure
- Clinical PET type assessed by surgeons from preoperatively preformed PET imaging
- timeFrame
- 1 week after surgery
- description
- Three surgeons will review the preoperative PET imaging and each will determine the clinical PET type as either K-type or Non-K type. Inter-surgeon agreement of clinical PET type will be determined. Clinicopathologic characteristics between K-type and Non-K type will also be analyzed.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Candidate for radical pancreatectomy due to pancreatic cancer without neoadjuvant treatment * Age between 20 years old and 80 years old * General performance status greater than 70 * Results of peroperative PET-CT available Exclusion Criteria: * Unresectable, locally advance and metastatic pancreatic cancer * Patients not wanting operation * ASA score of greater than 3 * History of chronic alcoholism ot drug abuse * Lack of patient compliance * Patients not agreeing to enroll in the study. * Patients unable to understand and sign the study agreement. * History of neoadjuvant treatment
References
Publications (0)
Data not yet available